搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
1 小时
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application ...
ophthalmologyadvisor
3 小时
Optic Complications in Rheumatic Diseases Linked to Poor Outcomes
Optic complications among hospitalized patients with RA, SLE, and SpA were linked to poor outcomes and higher health care costs, especially among Black and Asian patients.
5 小时
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies ...
DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...
5 小时
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to ...
Zacks.com on MSN
8 小时
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...
Lupus Foundation of America
10 小时
Lupus Research Highlights From American College of Rheumatology’s 2024 Scientific Meeting
The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...
11 小时
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...
BioSpace
11 小时
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eyes Second Phase III
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
rheumatologyadvisor
11 小时
Long-Term Anifrolumab Treatment Reduces Organ Damage in SLE
Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...
labiotech
13 小时
Six bispecific antibody companies you should know about
Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.
The Pharma Letter
13 小时
Fate Thera rockets on early data for FT819
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈